Hisamitsu Pharmaceutical (Japan)
Mylan (US)
UCB (Belgium)
Novartis (Switzerland)
and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany)
Johnson & Johnson (US)
Endo International (Ireland)
and Purdue Pharma (US).
Published | Pages | Publisher | Report code |
---|---|---|---|
Mar 2021 | 120 | DelveInsight | ASDR-575354 |
Hisamitsu Pharmaceutical (Japan)
Mylan (US)
UCB (Belgium)
Novartis (Switzerland)
and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany)
Johnson & Johnson (US)
Endo International (Ireland)
and Purdue Pharma (US).